knowledge -WSS

knowledge

author：entertainment 2025-09-06 02:16:19 - browse：97

Launching your first clinical trial is the type of announcement most biotech executives eagerly anticipate, hoping to celebrate with employees. But for Celsius Therapeutics CEO Tariq Kassum, it’s proving to be more difficult than he anticipated.

That’s because in recent days, Celsius, based in Cambridge, Mass., has been forced to conduct a round of layoffs, sources told STAT. Kassum confirmed around 75% of Celsius’ 40-person team had been laid off, and disclosed that the biotech has also been quietly paring back its pipeline this year. It shut down almost all early-stage research projects, including pausing all of its cancer drug work, in order to conserve enough cash for the Phase 1 trial it announced this week.

“It’s an incredibly bittersweet moment.… The cognitive dissonance there is just really, really hard,” Kassum told STAT. “But I do think that you’re seeing a lot of other companies doing what we are, which is, as painful as it is, to focus on the nearest term value drivers, the things that can get to patients the quickest, and make the painful decisions that allow you to live to fight another day.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： Readout Newsletter: Bayer study halts, Carmot to IPO, and more

WSS

Pfizer plans to depart BIO

Americans' trust in science, scientist continues decline: Report

CMS should re

Leukemia patients are helped by Syndax's new type of therapy

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

STAT letters to the editor on burnt

leisure time

knowledge

knowledge

Jerome Adams on the need for new antivirals for Covid

Roche to buy Carmot Therapeutics, developer of obesity drugs

How one medical school became remarkably diverse

Congenital heart disease patients face new threat of heart failure

Heart attack and stroke risk calculators need revising

FDA approves world's first CRISPR

Heart attack and stroke risk calculators need revising

FDA needs staff influx to meet gene therapy needs, Marks says

Medical records are filled with copy

Supreme Court wrestles with OxyContin maker's bankruptcy deal

focus

Congenital heart disease patients face new threat of heart failure

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

Morphosys mixed study results for blood cancer drug

Hospitals look to new technology to keep health care workers safe

Surge of respiratory disease in China has likely explanation

NYU radiologists take on the challenge of expensive MRI machines

Wikipedia

entertainment

leisure time

hotspot